Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PSTV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPlus Therapeutics regains Nasdaq compliance after 1-for-25 reverse stock split
Filed April 21, 2026 · Period ending April 20, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified the company on April 20 that it has regained compliance with the minimum $1.00 bid price requirement, avoiding delisting from the Nasdaq Capital Market.
Item 8.01 verify on EDGAR → -
high
The compliance was achieved through a 1-for-25 reverse stock split effective April 2, 2026, which consolidated every 25 shares into 1 share and proportionally increased the per-share price.
Item 8.01 verify on EDGAR → -
medium
The company issued a press release on April 21, 2026, attached as an exhibit; specific content not disclosed in the 8-K body.
Item 9.01 verify on EDGAR →
Summary
Plus Therapeutics has successfully cured its Nasdaq listing deficiency after implementing a steep 1-for-25 reverse stock split earlier this month. The company received formal notice from Nasdaq on April 20 confirming it now meets the exchange's minimum $1.00 bid price requirement for continued listing on the Capital Market. The reverse split, which became effective April 2, reduced the share count by 96% while proportionally boosting the per-share price above the compliance threshold.
For retail investors, this is a near-term positive—the immediate delisting threat is removed—but reverse splits often signal underlying weakness and can create downward price pressure as the stock adjusts. Existing shareholders now own far fewer shares at a higher nominal price, with no change in their economic stake. Watch whether the stock can maintain its bid price above $1.00 organically in coming months, as another deficiency notice would restart the compliance clock and potentially exhaust management's options to remain listed.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 20, 2026, Plus Therapeutics, Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a) (2) for continued listing on The Nasdaq Capital Market (“Nasdaq”).
The company received formal notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. This follows a one-for-twenty-five reverse stock split that became effective on April 2, 2026, which consolidated shares to raise the per-share price above Nasdaq's minimum threshold.
Added in current filing · verify on EDGAR →
The Notification Letter was sent following the implementation of a one-for-twenty-five reverse split of the Company’s common stock (the “Reverse Split”), which became effective on April 2, 2026.
The company executed a 1-for-25 reverse stock split effective April 2, 2026, which reduced the total number of outstanding shares by a factor of 25 while proportionally increasing the per-share price. This corporate action was the mechanism used to cure the prior bid price deficiency and avoid potential delisting from Nasdaq.
Event · Item 9.01 — Financial Statements and Exhibits
PLUS THERAPEUTICS filed an 8-K attaching a press release dated April 21, 2026; no material business event disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit | Number | Description | 99.1 | Press Release dated April 21, 2026.
The company attached a press release dated April 21, 2026 as Exhibit 99.1. The 8-K body does not disclose the content of the press release, so the nature and materiality of any announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify